Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid beta peptide (A β) and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase A β levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Moreover, the most accepted theory to explain the pathogenesis of AD is the amyloid hypothesis, which states that the cognitive disease phenotype is due to Aβ dyshomeostasis [6].”
BackgroundAstrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · cited 1×
“Although astrocytes show neuroprotective activity, activated astrocytes may aggravate neurodegenerative diseases [74].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015) · JAMA · doi:10.1001/jama.2015.13766 · Cited by 1,219
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
On the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556 · cited 1×
“neurodegeneration caused by progressive loss of neurons and their processes [5].”
BackgroundHomocysteine and folate as risk factors for dementia and Alzheimer disease
Ravaglia, G., Forti, P., Maioli, F., Martelli, M., Servadei, L., Brunetti, N., Porcellini, E., & Licastro, F. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.3.636 · Cited by 500
Hunt, A., Harrington, D., & Robinson, S. (2014) · BMJ · doi:10.1136/bmj.g5226 · Cited by 406
Neuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351 · cited 1×
“According to the neuroimmunomodulation theory of AD, the earliest CNS changes before the clinical onset of AD result from a chronic inflammatory response, which leads to abnormal tau phosphorylation and induces formation of PHFs and tau protein aggregates, ultimately resulting in cytoskeletal alterations [50].”
BackgroundIncreased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy
Lombardo, L., Foti, M., Ruggia, O., & Chiecchio, A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.12.022 · Cited by 350
The role of Aβ42 in Alzheimer's disease
Younkin, S. G. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80035-1 · Cited by 282
Association between proton pump inhibitor use and cognitive function in women
Lochhead, P., Hagan, K., Joshi, A. D., Khalili, H., Nguyen, L. H., Grodstein, F., & Chan, A. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.061 · Cited by 83
de la Coba Ortiz, C., Argüelles Arias, F., Martín de Argila de Prados, C., Júdez Gutiérrez, J., Linares Rodríguez, A., Ortega Alonso, A., Rodríguez de Santiago, E., Rodríguez-Téllez, M., Vera Mendoza, M. I., Aguilera Castro, L., et al. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4232/2016 · Cited by 54 · cited 1×
“, magnesium and vitamin B12 deficiency) [36] or direct effects on neurons after passage through the BBB.”
Background
Cited by
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Zang, C., Zhang, H., Xu, J., Zhang, H., Fouladvand, S., Havaldar, S., Cheng, F., Chen, K., Chen, Y., Glicksberg, B. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43929-1 · Cited by 69
“There is still no consensus on the role of PPIsand AD 28,29,35 .”
Gastric acid suppressants and cognitive decline in people with or without cognitive impairment
Wu, C., Xiong, L. Y., Ouk, M., Rabin, J. S., Herrmann, N., Lanctôt, K. L., Kapral, M. K., Law, M., Cogo‐Moreira, H., Edwards, J. D., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12243 · Cited by 13
Basaqr, R., & Babateen, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1648219 · Cited by 4
Metadata
- Authors
- Ortiz-Guerrero, G., Amador-Muñoz, D., Calderón-Ospina, C. A., López-Fuentes, D., & Nava Mesa, M. O.
- Venue
- Neural Plasticity
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Pages
- 1-9
- ISSN
- 1687-5443 (ISSN-L)
- 2090-5904
- OpenAlex
- W2793394439
- Cited by
- 115
- References
- 14
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.